Skip to main content

Table 2 Adjusted a hazard ratio (95% Confidence interval) of all-Cause and cardiovascular disease mortality, by eGFR categories among 16,010 participants of NHANES III (1988–1994) with follow-up till December 31, 2006

From: Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III)

   Categories of eGFR (ml/min/1.73 m2)
   ≥ 120 90-119 60-89 30-59 < 30
All-Cause Mortality       
EGFR CKD-EPI Participants, N 3,889 7,151 3,947 956 67
  Deaths, N 179 921 1,686 775 59
  HR 2.05 Reference 0.97 1.39 1.38
  (95% CI) (1.55-2.71)   (0.86-1.10) (1.17-1.65) (0.88-2.16)
EGFR MDRD Participants, N 2,729 6,604 5,606 1,015 56
  Deaths, N 228 805 1,788 750 49
  HR 1.70 Reference 0.94 1.31 1.96
  (95% CI) (1.36-2.14)   (0.84-1.05) (1.11-1.56) (1.11-3.44)
CVD Mortality       
EGFR CKD-EPI Participants, N 3,889 7,151 3,947 956 67
  Deaths, N 41 303 755 412 29
  HR 2.70 Reference 1.05 1.49 1.64
  (95% CI) (1.54-4.73)   (0.87-1.26) (1.16-1.92) (1.02-2.65)
EGFR MDRD Participants, N 2,729 6,604 5,606 1,015 56
  Deaths, N 64 278 774 401 23
  HR 1.53 Reference 0.95 1.32 2.17
  (95% CI) (0.96-2.45)   (0.79-1.13) (0.99-1.78) (1.18-3.98)
  1. Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVD, Cardiovascular Disease.
  2. a Adjusted for age, sex, race/ethnicity, prior CVD, diabetes, smoking, systolic and diastolic blood pressure, use of antihypertensive medications, body mass index, cholesterol, C-reactive protein category and albumin-to-creatinine ratio category.